Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bruno, R.
Right arrow Articles by Sheiner, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bruno, R.
Right arrow Articles by Sheiner, L. B.

Journal of Clinical Oncology, Vol 16, 187-196, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer

R Bruno, D Hille, A Riva, N Vivier, WW ten Bokkel Huinnink, AT van Oosterom, SB Kaye, J Verweij, FV Fossella, V Valero, JR Rigas, AD Seidman, B Chevallier, P Fumoleau, HA Burris, PM Ravdin and LB Sheiner
Drug Metabolism and Pharmacokinetics Department, Rhone-Poulenc Rorer, Antony, France. rene.bruno@rp_rorer.fr

PURPOSE: The population pharmacokinetic/pharmacodynamic (PK/PD) approach was prospectively integrated in the clinical development of docetaxel to assess the PK profile in a large population of patients and investigate systemic exposure as a prognostic factor for clinical outcome. PATIENTS AND METHODS: PK analysis was performed at first course in 24 phase II studies of docetaxel monotherapy using four randomized limited-sampling schedules. Bayesian estimates of clearance (CL), area under the concentration-time curve (AUC), and peak and duration of plasma levels greater than threshold levels were used as measures of exposure. PD data included for efficacy, response rate, time to first response, and time to progression (TTP) in breast cancer and non-small-cell lung cancer (NSCLC), and for toxicity, grade 4 neutropenia, and febrile neutropenia at first course and time to onset of fluid retention. PK/PD analysis was conducted using logistic and Cox multivariate regression models. RESULTS: PK protocol implementation was successful. Most of the patients registered (721 of 936, 77%) were sampled and 68% were assessable for PK (640 patients). First-course docetaxel AUC was a significant predictor (P = .0232) of TTP in NSCLC (n = 151). Docetaxel CL was a strong independent predictor (P < .0001) of both grade 4 neutropenia and febrile neutropenia (n = 582). Cumulative dose was the strongest predictor (P < .0001) of the time to onset of fluid retention (n = 631). However, the duration of exposure over 0.20 micromol/L (0.16 microg/mL) at first course was an independent predictor (P = .0029). Few patients (n = 25, 4%) received the recommended dexamethasone premedication. CONCLUSION: First-course docetaxel PK is a predictor of first-course hematologic toxicity, but also of fluid retention, which is cumulative in nature. Patients with elevated hepatic enzymes have a 27% reduction in docetaxel CL and are at a higher risk of toxicity. A starting dose of 75 mg/m2 is currently being evaluated in this population. Prospective implementation of large- scale population PK/PD evaluation is feasible in early drug development and this approach generates clinically relevant findings.


This article has been cited by other articles:


Home page
 JCOHome page
D. Rathkopf, M. A. Carducci, M. J. Morris, S. F. Slovin, M. A. Eisenberger, R. Pili, S. R. Denmeade, M. Kelsen, T. Curley, M. Halter, et al.
Phase II Trial of Docetaxel With Rapid Androgen Cycling for Progressive Noncastrate Prostate Cancer
J. Clin. Oncol., June 20, 2008; 26(18): 2959 - 2965.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. R. Judson
Imatinib for Patients With Liver or Kidney Dysfunction: No Need to Modify the Dose
J. Clin. Oncol., February 1, 2008; 26(4): 521 - 522.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. M. Sissung, R. Danesi, D. K. Price, S. M. Steinberg, R. de Wit, M. Zahid, N. Gaikwad, E. Cavalieri, W. L. Dahut, D. L. Sackett, et al.
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel
Mol. Cancer Ther., January 1, 2008; 7(1): 19 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
S. M. Lichtman
Pharmacology of Antineoplastic Agents for Older Patients
ASCO Educational Book, January 1, 2008; 2008(1): 210 - 214.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L.-S. Tham, N. H.G. Holford, S.-Y. Hor, T. Tan, L. Wang, R.-C. Lim, H.-S. Lee, S.-C. Lee, and B.-C. Goh
Lack of Association of Single-Nucleotide Polymorphisms in Pregnane X Receptor, Hepatic Nuclear Factor 4{alpha}, and Constitutive Androstane Receptor with Docetaxel Pharmacokinetics
Clin. Cancer Res., December 1, 2007; 13(23): 7126 - 7132.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro
International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature
J. Clin. Oncol., May 10, 2007; 25(14): 1832 - 1843.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. K. Engels, F. A. de Jong, A. Sparreboom, R. A. A. Mathot, W. J. Loos, J. J. E. M. Kitzen, P. de Bruijn, J. Verweij, and R. H. J. Mathijssen
Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel
Oncologist, March 1, 2007; 12(3): 291 - 300.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J Alexandre, E Rey, V Girre, S Grabar, A Tran, V Montheil, F Rabillon, V Dieras, V Jullien, P Herait, et al.
Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study
Ann. Onc., January 1, 2007; 18(1): 168 - 172.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Kloft, J. Wallin, A. Henningsson, E. Chatelut, and M. O. Karlsson
Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: Comparison across Anticancer Drugs.
Clin. Cancer Res., September 15, 2006; 12(18): 5481 - 5490.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. N.A. Bijman, G. P. van Nieuw Amerongen, N. Laurens, V. W.M. van Hinsbergh, and E. Boven
Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton.
Mol. Cancer Ther., September 1, 2006; 5(9): 2348 - 2357.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. C. Cox, J. Low, J. Lee, J. Walshe, N. Denduluri, A. Berman, M. G. Permenter, W. P. Petros, D. K. Price, W. D. Figg, et al.
Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel
Clin. Cancer Res., August 1, 2006; 12(15): 4636 - 4640.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
M. Zhu and M. Pfister
Optimizing Benefit/Risk Profiles of New Oncology Agents With Modeling and Simulation
Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 45 - 49.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. A. Messersmith, S. D. Baker, L. Lassiter, R. A. Sullivan, K. Dinh, V. I. Almuete, J. J. Wright, R. C. Donehower, M. A. Carducci, and D. K. Armstrong
Phase I Trial of Bortezomib in Combination with Docetaxel in Patients with Advanced Solid Tumors
Clin. Cancer Res., February 15, 2006; 12(4): 1270 - 1275.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
S. Dubey, P. Hutson, D. Alberti, R. Arzoomanian, K. Binger, J. Volkman, C. Feierabend, G. Wilding, and J. H Schiller
Phase I study of docetaxel and topotecan in patients with advanced malignancies
Journal of Oncology Pharmacy Practice, December 1, 2005; 11(4): 132 - 138.
[Abstract] [PDF]

Home page
 Ann OncolHome page
O. Pagani, C. Sessa, F. Nole, E. Munzone, D. Crivellari, D. Lombardi, B. Thurlimann, D. Hess, R. Graffeo, M. Ruggeri, et al.
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
Ann. Onc., October 1, 2005; 16(10): 1609 - 1617.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
G. H. Yoo, G. Subramanian, R. R. Boinpally, A. Iskander, N. Shehadeh, J. Oliver, W. Ezzat, M. P. Piechocki, J. F. Ensley, H.-S. Lin, et al.
An In Vivo Evaluation of Docetaxel Delivered Intratumorally in Head and Neck Squamous Cell Carcinoma
Arch Otolaryngol Head Neck Surg, May 1, 2005; 131(5): 418 - 429.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. ten Tije, J. Verweij, M. A. Carducci, W. Graveland, T. Rogers, T. Pronk, M.P. Verbruggen, F. Dawkins, and S. D. Baker
Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the Elderly
J. Clin. Oncol., February 20, 2005; 23(6): 1070 - 1077.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Yamamoto, T. Tamura, H. Murakami, T. Shimoyama, H. Nokihara, Y. Ueda, I. Sekine, H. Kunitoh, Y. Ohe, T. Kodama, et al.
Randomized Pharmacokinetic and Pharmacodynamic Study of Docetaxel: Dosing Based on Body-Surface Area Compared With Individualized Dosing Based on Cytochrome P450 Activity Estimated Using a Urinary Metabolite of Exogenous Cortisol
J. Clin. Oncol., February 20, 2005; 23(6): 1061 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Dagher, N. Li, S. Abraham, A. Rahman, R. Sridhara, and R. Pazdur
Approval Summary: Docetaxel in Combination with Prednisone for the Treatment of Androgen-Independent Hormone-Refractory Prostate Cancer
Clin. Cancer Res., December 15, 2004; 10(24): 8147 - 8151.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. D. Baker, R. H. N. van Schaik, L. P. Rivory, A. J. ten Tije, K. Dinh, W. J. Graveland, P. W. Schenk, K. A. Charles, S. J. Clarke, M. A. Carducci, et al.
Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients
Clin. Cancer Res., December 15, 2004; 10(24): 8341 - 8350.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. M. Fracasso, L. J. Goldstein, D. P. de Alwis, J. S. Rader, M. A. Arquette, S. A. Goodner, L. P. Wright, C. L. Fears, R. J. Gazak, V. A. M. Andre, et al.
Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies
Clin. Cancer Res., November 1, 2004; 10(21): 7220 - 7228.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
B Porta-Oltra, J. Perez-Ruixo, M Climente-Marti, M Merino-Sanjuan, D Almenar-Cubells, and N. Jimenez-Torres
Population pharmacokinetics of 5-fluorouracil in colorectal cancer patients
Journal of Oncology Pharmacy Practice, September 1, 2004; 10(3): 155 - 167.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
A. W. Tolcher, J. Kuhn, G. Schwartz, A. Patnaik, L. A. Hammond, I. Thompson, H. Fingert, D. Bushnell, S. Malik, J. Kreisberg, et al.
A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer
Clin. Cancer Res., August 1, 2004; 10(15): 5048 - 5057.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Minami, Y. Ohe, S. Niho, K. Goto, H. Ohmatsu, K. Kubota, R. Kakinuma, Y. Nishiwaki, H. Nokihara, I. Sekine, et al.
Comparison of Pharmacokinetics and Pharmacodynamics of Docetaxel and Cisplatin in Elderly and Non-Elderly Patients: Why Is Toxicity Increased in Elderly Patients?
J. Clin. Oncol., July 15, 2004; 22(14): 2901 - 2908.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Gligorov and J. P. Lotz
Preclinical Pharmacology of the Taxanes: Implications of the Differences
Oncologist, June 2, 2004; 9(suppl_2): 3 - 8.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Ostermann, C. Csajka, T. Buclin, S. Leyvraz, F. Lejeune, L. A. Decosterd, and R. Stupp
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients
Clin. Cancer Res., June 1, 2004; 10(11): 3728 - 3736.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. D. Baker, M. Zhao, C. K. K. Lee, J. Verweij, Y. Zabelina, J. R. Brahmer, A. C. Wolff, A. Sparreboom, and M. A. Carducci
Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel
Clin. Cancer Res., March 15, 2004; 10(6): 1976 - 1983.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Panetta, L. C. Iacono, P. C. Adamson, and C. F. Stewart
The Importance of Pharmacokinetic Limited Sampling Models for Childhood Cancer Drug Development
Clin. Cancer Res., November 1, 2003; 9(14): 5068 - 5077.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Trent, V. Valero, D. J. Booser, L. T. Esparza-Guerra, N. Ibrahim, Z. Rahman, L. Vernillet, S. Patel, C. L. David, J. L. Murray, et al.
A Phase I Study of Docetaxel Plus Cyclophosphamide in Solid Tumors followed by a Phase II Study as First-Line Therapy in Metastatic Breast Cancer
Clin. Cancer Res., July 1, 2003; 9(7): 2426 - 2434.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. L. R. Mitchell, R. Basser, M. Chipman, A. Grigg, J. Cebon, I. D. Davis, J. Zalcberg, S. Ng, F. Appia, and M. Green
A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours
Ann. Onc., May 1, 2003; 14(5): 788 - 794.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Bruno, R. Olivares, J. Berille, P. Chaikin, N. Vivier, L. Hammershaimb, G. R. Rhodes, and J. R. Rigas
{alpha}-1-Acid Glycoprotein As an Independent Predictor for Treatment Effects and a Prognostic Factor of Survival in Patients with Non-small Cell Lung Cancer Treated with Docetaxel
Clin. Cancer Res., March 1, 2003; 9(3): 1077 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. E. Friberg, A. Henningsson, H. Maas, L. Nguyen, and M. O. Karlsson
Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs
J. Clin. Oncol., December 15, 2002; 20(24): 4713 - 4721.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C.M.F. Kruijtzer, J.H. Beijnen, and J.H.M. Schellens
Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview
Oncologist, December 1, 2002; 7(6): 516 - 530.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Ch. van Kesteren, R. A.A. Mathot, E. Raymond, J. P. Armand, Ch. Dittrich, H. Dumez, H. Roche, J. P. Droz, C. Punt, M. Ravic, et al.
Population Pharmacokinetics of the Novel Anticancer Agent E7070 During Four Phase I Studies: Model Building and Validation
J. Clin. Oncol., October 1, 2002; 20(19): 4065 - 4073.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B.-C. Goh, S.-C. Lee, L.-Z. Wang, L. Fan, J.-Y. Guo, J. Lamba, E. Schuetz, R. Lim, H.-L. Lim, A.-B. Ong, et al.
Explaining Interindividual Variability of Docetaxel Pharmacokinetics and Pharmacodynamics in Asians Through Phenotyping and Genotyping Strategies
J. Clin. Oncol., September 1, 2002; 20(17): 3683 - 3690.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Nadella, C. Shapiro, G. A. Otterson, M. Hauger, S. Erdal, E. Kraut, S. Clinton, M. Shah, M. Stanek, P. Monk, et al.
Pharmacobiologically Based Scheduling of Capecitabine and Docetaxel Results in Antitumor Activity in Resistant Human Malignancies
J. Clin. Oncol., June 1, 2002; 20(11): 2616 - 2623.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. P. Piechocki, F. Lonardo, J. F. Ensley, T. Nguyen, H. Kim, and G. H. Yoo
Anticancer Activity of Docetaxel in Murine Salivary Gland Carcinoma
Clin. Cancer Res., March 1, 2002; 8(3): 870 - 877.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Freyer, P. Hennebert, A. Awada, T. Gil, J. Kerger, J. Selleslags, C. Brassinne, M. Piccart, and D. de Valeriola
Influence of Amifostine on the Toxicity and Pharmacokinetics of Docetaxel in Metastatic Breast Cancer Patients: A Pilot Study
Clin. Cancer Res., January 1, 2002; 8(1): 95 - 102.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Minotti, A. Saponiero, S. Licata, P. Menna, A. M. Calafiore, G. Teodori, and L. Gianni
Paclitaxel and Docetaxel Enhance the Metabolism of Doxorubicin to Toxic Species in Human Myocardium
Clin. Cancer Res., June 1, 2001; 7(6): 1511 - 1515.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Crown
Docetaxel: Overview of an Active Drug for Breast Cancer
Oncologist, June 1, 2001; 6(2008): 1 - 4.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. J. Sweeney, K. D. Miller, S. E. Sissons, S. Nozaki, D. K. Heilman, J. Shen, and G. W. Sledge Jr.
The Antiangiogenic Property of Docetaxel Is Synergistic with a Recombinant Humanized Monoclonal Antibody against Vascular Endothelial Growth Factor or 2-Methoxyestradiol but Antagonized by Endothelial Growth Factors
Cancer Res., April 1, 2001; 61(8): 3369 - 3372.
[Abstract] [Full Text]

Home page
 JCOHome page
M. Ando, T. Watanabe, K. Nagata, M. Narabayashi, I. Adachi, and N. Katsumata
Efficacy of Docetaxel 60 mg/m2 in Patients With Metastatic Breast Cancer According to the Status of Anthracycline Resistance
J. Clin. Oncol., January 15, 2001; 19(2): 336 - 342.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. C. Zamboni, M. J. Egorin, D. A. Van Echo, R. S. Day, B. R. Meisenberg, S. E. Brooks, L. A. Doyle, N. N. Nemieboka, J. M. Dobson, N. S. Tait, et al.
Pharmacokinetic and Pharmacodynamic Study of the Combination of Docetaxel and Topotecan in Patients With Solid Tumors
J. Clin. Oncol., September 18, 2000; 18(18): 3288 - 3294.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
D. Frame
Introduction to taxane pharmacokinetics and pharmacodynamics
Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3_suppl): S23 - S27.
[Abstract] [PDF]

Home page
 JCOHome page
J. A. Sparano, A. O'Neill, P. L. Schaefer, C. I. Falkson, and W. C. Wood
Phase II Trial of Doxorubicin and Docetaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: Eastern Cooperative Oncology Group Study E1196
J. Clin. Oncol., June 12, 2000; 18(12): 2369 - 2377.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Gallo, P. B. Laub, E. K. Rowinsky, L. B. Grochow, and S. D. Baker
Population Pharmacokinetic Model for Topotecan Derived From Phase I Clinical Trials
J. Clin. Oncol., June 12, 2000; 18(12): 2459 - 2467.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Yamamoto, T. Tamura, Y. Kamiya, I. Sekine, H. Kunitoh, and N. Saijo
Correlation Between Docetaxel Clearance and Estimated Cytochrome P450 Activity by Urinary Metabolite of Exogenous Cortisol
J. Clin. Oncol., June 11, 2000; 18(11): 2301 - 2308.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
J. M Kolesar
Docetaxel in hepatic impairment
Journal of Oncology Pharmacy Practice, June 1, 2000; 6(2): 43 - 49.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
R. P. Kline, E. X. Wu, D. P. Petrylak, M. Szabolcs, P. O. Alderson, M. L. Weisfeldt, P. Cannon, and J. Katz
Rapid in Vivo Monitoring of Chemotherapeutic Response Using Weighted Sodium Magnetic Resonance Imaging
Clin. Cancer Res., June 1, 2000; 6(6): 2146 - 2156.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
J. Hirth, P. B. Watkins, M. Strawderman, A. Schott, R. Bruno, and L. H. Baker
The Effect of an Individual's Cytochrome CYP3A4 Activity on Docetaxel Clearance
Clin. Cancer Res., April 1, 2000; 6(4): 1255 - 1258.
[Abstract] [Full Text]

Home page
 JCOHome page
J. Alexandre, P. Bleuzen, J. Bonneterre, W. Sutherland, J. L. Misset, J.-P. Guastalla, P. Viens, S. Faivre, A. Chahine, M. Spielman, et al.
Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients
J. Clin. Oncol., February 1, 2000; 18(3): 562 - 562.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Van Den Neste, Dominique de Valeriola, J. Kerger, H. Bleiberg, Z. Kusenda, C. Brassinne, S. Bartholomeus, J. Selleslags, P. Hennebert, H. Wythouck, et al.
A Phase I and Pharmacokinetic Study of Docetaxel Administered in Combination with Continuous Intravenous Infusion of 5-Fluorouracil in Patients with Advanced Solid Tumors
Clin. Cancer Res., January 1, 2000; 6(1): 64 - 71.
[Abstract] [Full Text]

Home page
 JCOHome page
E. Salminen, M. Bergman, S. Huhtala, and E. Ekholm
Docetaxel: Standard Recommended Dose of 100 mg/m2 Is Effective But Not Feasible for Some Metastatic Breast Cancer Patients Heavily Pretreated With ChemotherapyA Phase II Single-Center Study
J. Clin. Oncol., April 1, 1999; 17(4): 1127 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Esposito, M. Venturini, M.O. Vannozzi, G. Tolino, G. Lunardi, O. Garrone, C. Angiolini, M. Viale, M. Bergaglio, L. Del Mastro, et al.
Comparative Effects of Paclitaxel and Docetaxel on the Metabolism and Pharmacokinetics of Epirubicin in Breast Cancer Patients
J. Clin. Oncol., April 1, 1999; 17(4): 1132 - 1132.
[Abstract] [Full Text] [PDF]